<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02004717</url>
  </required_header>
  <id_info>
    <org_study_id>DS8895-A-J101</org_study_id>
    <nct_id>NCT02004717</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-8895a in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, sequential dose escalation and expansion study to evaluate the safety,
      tolerability, and pharmacokinetics of DS-8895a in Japanese subjects with advanced solid
      tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of participants experiencing dose limiting toxicities</measure>
    <time_frame>day 1 through day 28</time_frame>
    <description>to investigate the safety of DS-8895a reporting on frequency and seriousness of treatment emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of participants experiencing clinical or laboratory adverse events</measure>
    <time_frame>from start of treatment to end of treatment, on expected average 12 weeks</time_frame>
    <description>to investigate the safety of DS-8895a reporting on frequency and seriousness of treatment emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum pharmacokinetics of DS-8895a</measure>
    <time_frame>Cycle 1 - days 1, 2, 4, 8 and 15; Cycle 2-days 1, 2, 4, 8 and 15; Cycle 3 and on- days 1; end of study; 45 days post last dose</time_frame>
    <description>pharmacokinetics (Area Under the Curve-AUC, Terminal Elimination half-life-t1/2, Total Body Clearance) of DS-8895a in Japanese subjects with advanced solid tumors, and also to investigate the recommended dose of DS-8895a for subsequent clinical studies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>level of anti-DS-8895a (HAHA) antibody</measure>
    <time_frame>Cycle 1 days 1 and 15; Cycle 2 day 1; end of study; 45 days post-last-dose</time_frame>
    <description>Human anti-human antibody (HAHA) profile for DS-8895a [Time Frame: Cycle 1 - days 1, and 15; Cycle 2 and on - days 1; end of study; 45 days post last dose] The presence of HAHA (anti-DS-8895a neutralizing antibody) in serum will be assessed&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>every 6 weeks</time_frame>
    <description>proportion of subjects with the best overall response of stable disease or better will be measured every 6 weeks until study drug discontinued.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic effects in blood</measure>
    <time_frame>day 1 and 2</time_frame>
    <description>effects on blood will be determined at day 1 and 2 of each cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic effects in tumors</measure>
    <time_frame>baseline and day 1 of cycle 2</time_frame>
    <description>effects on tumor cells will be determined at baseline and day 1 of cycle 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>every 6 weeks</time_frame>
    <description>sum of complete response and partial response rates measured every 6 weeks until study drug discontinuation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>dose escalation then expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg. Six dose levels are planned: level 1,0.1 mg/kg; level 2,0.3 mg/kg; level 3, 1.0 mg/kg; level 4,3.0 mg/kg; level 5,10 mg/kg; level 6,20 mg/kg.
Dose Expansion - Up to 20 subjects will be enrolled and treated at the dose determined in Dose Escalation arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-8895a</intervention_name>
    <arm_group_label>dose escalation then expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced solid tumor that is refractory to standard treatment, or for which no
             standard treatment is available.

          -  Eastern Cooperative Oncology Group performance status(PS) of 0 or 1

        Exclusion Criteria:

          -  Have any of the following concomitant disease or had the history of having following
             disease within 6 months before enrollment:

        Cardiac failure (NYHA â‰¥ ClassIII), myocardial infarction, cerebral infarction, unstable
        angina, arrhythmia requiring treatment, coronary-artery/peripheral artery bypass surgery,
        cerebrovascular disease, pulmonary thromboembolism, deep-vein thrombosis or clinically
        severe thromboembolic event, or clinically severe pulmonary disease (eg, interstitial
        pneumonia, pulmonary fibrosis, radiation pneumonia, drug induced pneumonia)

          -  Severe or uncontrolled concomitant disease.

          -  Clinically active brain metastases defined as symptomatic or requiring treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced solid tumor</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Oncology</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

